Mapping SARS-CoV-2 immunity after an XBB.1.5 booster by antigenic cartography of merged human and hamster sera.

IF 7.2 1区 医学 Q1 IMMUNOLOGY
Marta Bermejo-Jambrina, Antonia Netzl, Ludwig Knabl, Melanie M Schmitt, Annika Rössler, Gagandeep Singh, Seok-Chan Park, Michael Schotsaert, Anna Mykytyn, Bart L Haagmans, Wegene Borena, Derek J Smith, Janine Kimpel
{"title":"Mapping SARS-CoV-2 immunity after an XBB.1.5 booster by antigenic cartography of merged human and hamster sera.","authors":"Marta Bermejo-Jambrina, Antonia Netzl, Ludwig Knabl, Melanie M Schmitt, Annika Rössler, Gagandeep Singh, Seok-Chan Park, Michael Schotsaert, Anna Mykytyn, Bart L Haagmans, Wegene Borena, Derek J Smith, Janine Kimpel","doi":"10.1038/s41541-026-01516-7","DOIUrl":null,"url":null,"abstract":"<p><p>The ongoing evolution of SARS-CoV-2, particularly the emergence and rapid spread of new immune-evasive variants, continues to challenge the durability of vaccine-induced protection. Understanding how repeated variant exposures shape neutralizing antibody breadth is therefore essential for optimizing booster design. Here, we investigated polyclonal neutralizing antibody responses in individuals who received a bivalent (ancestral + BA.4/5) boost followed by an additional monovalent XBB.1.5 boost, with and without breakthrough infection, against a diverse panel of SARS-CoV-2 variants. To visualize human multi-exposure immunity in antigenic space via antibody landscapes, we extended our existing human sera-based antigenic map with hamster sera infected with more recent variants. The hamster sera allowed us to map BA.2.86 and JN.1 variants, which largely escape human single exposure sera. Our analysis of human multi-exposure sera revealed that the number and type of exposures significantly shaped antibody landscapes. The XBB.1.5 booster immunization notably increased neutralizing antibody titers across variants, elevating the height of the antibody landscape. However, titers against more recent Omicron variants, such as JN.1, were low despite booster administration. These findings highlight the dynamic nature of SARS-CoV-2 immunity and emphasize the need for continuous monitoring and adaptation of vaccine strategies to maintain effective protection against emerging variants.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2000,"publicationDate":"2026-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41541-026-01516-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The ongoing evolution of SARS-CoV-2, particularly the emergence and rapid spread of new immune-evasive variants, continues to challenge the durability of vaccine-induced protection. Understanding how repeated variant exposures shape neutralizing antibody breadth is therefore essential for optimizing booster design. Here, we investigated polyclonal neutralizing antibody responses in individuals who received a bivalent (ancestral + BA.4/5) boost followed by an additional monovalent XBB.1.5 boost, with and without breakthrough infection, against a diverse panel of SARS-CoV-2 variants. To visualize human multi-exposure immunity in antigenic space via antibody landscapes, we extended our existing human sera-based antigenic map with hamster sera infected with more recent variants. The hamster sera allowed us to map BA.2.86 and JN.1 variants, which largely escape human single exposure sera. Our analysis of human multi-exposure sera revealed that the number and type of exposures significantly shaped antibody landscapes. The XBB.1.5 booster immunization notably increased neutralizing antibody titers across variants, elevating the height of the antibody landscape. However, titers against more recent Omicron variants, such as JN.1, were low despite booster administration. These findings highlight the dynamic nature of SARS-CoV-2 immunity and emphasize the need for continuous monitoring and adaptation of vaccine strategies to maintain effective protection against emerging variants.

用合并的人和仓鼠血清抗原制图绘制XBB.1.5增强剂后SARS-CoV-2免疫
SARS-CoV-2的持续演变,特别是新的免疫逃避变体的出现和迅速传播,继续挑战疫苗诱导保护的持久性。因此,了解反复变异暴露如何形成中和抗体宽度对于优化增强剂设计至关重要。在这里,我们研究了在有和没有突破性感染的情况下,接受二价(祖代+ BA.4/5)增强和额外单价XBB.1.5增强的个体中,针对多种SARS-CoV-2变体的多克隆中和抗体反应。为了通过抗体景观在抗原空间中可视化人类多暴露免疫,我们用感染了最新变体的仓鼠血清扩展了现有的基于人类血清的抗原图谱。仓鼠血清使我们能够绘制BA.2.86和JN.1变异,它们在很大程度上逃脱了人类单次暴露的血清。我们对人类多次暴露血清的分析显示,暴露的数量和类型显着塑造了抗体景观。XBB.1.5加强免疫显著提高了各变异的中和抗体滴度,提高了抗体图谱的高度。然而,尽管给予加强治疗,对最近的欧米克隆变体(如JN.1)的滴度很低。这些发现突出了SARS-CoV-2免疫的动态性质,并强调需要持续监测和调整疫苗策略,以保持对新出现的变体的有效保护。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
NPJ Vaccines
NPJ Vaccines Immunology and Microbiology-Immunology
CiteScore
11.90
自引率
4.30%
发文量
146
审稿时长
11 weeks
期刊介绍: Online-only and open access, npj Vaccines is dedicated to highlighting the most important scientific advances in vaccine research and development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书